The nitazoxanide drug was molecularly docked with the top eight anti-HCC core targets (SRC, EGFR, CASP3, MMP9, mTOR, HIF1A, ERBB2, and PPARG), and the findings are shown in Table 1. This evidence concerns the gene CASP3 and hepatocellular carcinoma.